Core Viewpoint - Quantum BioPharma Ltd. strongly refutes allegations of securities law violations made by The Schall Law Firm and DJS Law Group, describing the claims as vague and unsubstantiated [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [5]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5]. Legal Response - The company views the announcements from the law firms as opportunistic litigation tactics aimed at exploiting public markets without merit [3]. - Quantum BioPharma is reviewing the conduct of the law firms involved and plans to take appropriate action to protect its reputation [3]. Call for Information - The company invites individuals or entities who feel they have been treated unfairly by the law firms to come forward, assuring confidentiality [4].
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group